1 / 10

Strategic Critical Path Research

Strategic Critical Path Research. Keith O. Webber, Ph.D. Acting Director, OBP Office of Pharmaceutical Science ACPS Meeting October 19 th , 2004. Drug Development Path. Discovery Candidate selection Pre-Clinical Studies Clinical Studies Commercialization

lee-becker
Download Presentation

Strategic Critical Path Research

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Strategic Critical Path Research Keith O. Webber, Ph.D. Acting Director, OBP Office of Pharmaceutical Science ACPS Meeting October 19th, 2004

  2. Drug Development Path • Discovery • Candidate selection • Pre-Clinical Studies • Clinical Studies • Commercialization • Post-Approval Manufacturing Optimization • New Indications

  3. Empirical vs. Guided Development Drug Development must be a learning process in order to make intelligent decisions regarding: • Candidate selection • Dosage form and formulation • Clinical indication • Clinical endpoints • Adverse event monitoring • Manufacturing methods

  4. Empirical vs. Guided Development Goal: To establish a knowledge base and the tools necessary to predict the probable success of given products and manufacturing methods and to foster the development of products with a high likelihood of success.

  5. Office of Pharmaceutical Science • Informatics and Computational Safety Analysis Staff • Office of New Drug Chemistry • Office of Generic Drugs • Office of Testing and Research • Office of Biotechnology Products

  6. OPS Critical Path Research • Candidate selection • Dosage form development and evaluation • Toxicity predictions • Bioavailability and bioequivalence prediction • Metabolism prediction • Immunogenicity • Biomarker validity • Mechanism of action • Pharmacogenomics • Manufacturing methodologies

  7. Critical Path Research Strategies Coordinate cooperative research activities: • Predictive modeling based on data from: • Regulatory submissions • FDA laboratory research • Laboratory research from outside collaborators • Published literature

  8. Critical Path Research Strategies Coordinate cooperative research activities: • Laboratory research • OTR • Div. of Applied Pharmacology Research • Div. of Product Quality Research • Div. of Pharmaceutical Analysis • OBP • Div. of Monoclonal Antibodies • Div. of Therapeutic Products • Other FDA Centers • Outside collaborations (Academia, Industry, other Gov’t.)

  9. Utilization of Information • Disseminate to manufacturers via: • Public forums • Guidance documents • Regulatory meetings (pre-IND, pre-NDA, pre-BLA) • Disseminate to reviewers: • Training programs • Mentoring • To enhance the application review process

  10. Questions • Are we focusing on the appropriate Critical Path topics? • Are there others that we should be addressing through our research programs? • How should we identify Critical Path issues in the future and how should we prioritize them?

More Related